{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Solution&page=5",
    "query": {
      "intervention": "Control Solution",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 3228,
    "total_pages": 323,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Solution&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Solution&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T12:00:34.127Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04166552",
      "title": "Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Diffuse Cutaneous Systemic Sclerosis",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Patients will be randomized to receive EHP-101 or Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emerald Health Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 36,
      "start_date": "2020-06-11",
      "completion_date": "2024-10",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-22T12:00:34.127Z",
      "location_count": 13,
      "location_summary": "Phoenix, Arizona • Huntington Beach, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04166552"
    },
    {
      "nct_id": "NCT02281318",
      "title": "Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Mepolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "SOC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 556,
      "start_date": "2014-12-11",
      "completion_date": "2016-06-10",
      "has_results": true,
      "last_update_posted_date": "2018-08-06",
      "last_synced_at": "2026-10-22T12:00:34.127Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02281318"
    },
    {
      "nct_id": "NCT04075513",
      "title": "Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin glargine, 300 U/ml",
          "type": "DRUG"
        },
        {
          "name": "Insulin degludec, 100U/ml",
          "type": "DRUG"
        },
        {
          "name": "Background therapy: Rapid acting insulin analogs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 343,
      "start_date": "2019-10-09",
      "completion_date": "2021-09-16",
      "has_results": true,
      "last_update_posted_date": "2022-11-14",
      "last_synced_at": "2026-10-22T12:00:34.127Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04075513"
    },
    {
      "nct_id": "NCT03691662",
      "title": "A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma and Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "DE-117 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Timolol Maleate Ophthalmic Solution 0.5%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Months and older"
      },
      "enrollment_count": 417,
      "start_date": "2018-09-27",
      "completion_date": "2019-10-23",
      "has_results": true,
      "last_update_posted_date": "2023-08-09",
      "last_synced_at": "2026-10-22T12:00:34.127Z",
      "location_count": 34,
      "location_summary": "Chandler, Arizona • Prescott, Arizona • Glendale, California + 29 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Prescott",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03691662"
    },
    {
      "nct_id": "NCT02342691",
      "title": "Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gingival Inflammation"
      ],
      "interventions": [
        {
          "name": "BLXA4",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral rinse",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Forsyth Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 127,
      "start_date": "2015-04",
      "completion_date": "2019-08-30",
      "has_results": true,
      "last_update_posted_date": "2023-12-20",
      "last_synced_at": "2026-10-22T12:00:34.127Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02342691"
    },
    {
      "nct_id": "NCT05850520",
      "title": "A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Macular Edema Secondary to Retinal Vein Occlusion"
      ],
      "interventions": [
        {
          "name": "Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose",
          "type": "DRUG"
        },
        {
          "name": "Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg",
          "type": "DRUG"
        },
        {
          "name": "Sham",
          "type": "DRUG"
        },
        {
          "name": "Fluorescein",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 892,
      "start_date": "2023-05-15",
      "completion_date": "2025-05-27",
      "has_results": true,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-10-22T12:00:34.127Z",
      "location_count": 53,
      "location_summary": "Fullerton, California • Long Beach, California • Mountain View, California + 48 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05850520"
    },
    {
      "nct_id": "NCT03831997",
      "title": "Effect of Different Intravenous Fluids on Post-operative Chronic Subdural Hematoma Size and Recurrence",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Subdural Hematoma"
      ],
      "interventions": [
        {
          "name": "Dextrose 5% W/ Sodium Chloride 0.225%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Carilion Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 35,
      "start_date": "2019-01-17",
      "completion_date": "2022-06-01",
      "has_results": false,
      "last_update_posted_date": "2020-10-08",
      "last_synced_at": "2026-10-22T12:00:34.127Z",
      "location_count": 1,
      "location_summary": "Roanoke, Virginia",
      "locations": [
        {
          "city": "Roanoke",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03831997"
    },
    {
      "nct_id": "NCT01286168",
      "title": "Trial of Drain Antisepsis After Tissue Expander Breast Reconstruction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nonmalignant Breast Conditions",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Sodium hypochlorite (Dakin's Solution)",
          "type": "DEVICE"
        },
        {
          "name": "Chlorhexidine gluconate disk",
          "type": "DEVICE"
        },
        {
          "name": "Control",
          "type": "PROCEDURE"
        },
        {
          "name": "Occlusive Adhesive Dressing",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 110,
      "start_date": "2011-05",
      "completion_date": "2013-11",
      "has_results": true,
      "last_update_posted_date": "2014-12-19",
      "last_synced_at": "2026-10-22T12:00:34.127Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Rochester, Minnesota",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01286168"
    },
    {
      "nct_id": "NCT02413255",
      "title": "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TAK-020",
          "type": "DRUG"
        },
        {
          "name": "TAK-020 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 120,
      "start_date": "2015-03-18",
      "completion_date": "2017-05-04",
      "has_results": true,
      "last_update_posted_date": "2019-01-07",
      "last_synced_at": "2026-10-22T12:00:34.127Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02413255"
    },
    {
      "nct_id": "NCT02669862",
      "title": "A Study of A-101 Solution in Subjects With Common Warts.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Common Warts"
      ],
      "interventions": [
        {
          "name": "A-101 Solution 40",
          "type": "DRUG"
        },
        {
          "name": "A-101 Solution 45",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2015-12-21",
      "completion_date": "2016-09-16",
      "has_results": true,
      "last_update_posted_date": "2018-12-07",
      "last_synced_at": "2026-10-22T12:00:34.127Z",
      "location_count": 1,
      "location_summary": "Wayne, Pennsylvania",
      "locations": [
        {
          "city": "Wayne",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02669862"
    }
  ]
}